Product imageResearch use only

CAT. NO. DC60475Featured

CL4F8-6

Research highlights

50/38.5/10/1.5 mol% formulationN/P 10; pKa 6.1488.78 nm; PDI 0.022; EE 99.4%54% liver editing and 77% serum TTR reduction

Pack size & price

USD

Add the cited formulation componentsSelected CL4F8-6 pack + every supporting component at 100 mg each+US$450 / set

Supporting components

Cholesterol DCD-041 · 100 mg+DSPC DC57005 · 100 mg+DMG-PEG2000 DC40169 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

Total$700

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

CL4F8-6 is an ionizable cationic lipid (pKa = 6.14) that has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs).1 LNPs containing CL4F8-6 and encapsulating an mRNA reporter accumulate specifically in the mouse liver after intravenous administration. LNPs containing CL4F8-6 and encapsulating mRNA encoding the Cas9 nuclease (mCas9) and single-guide RNA (sgRNA) targeting Ttr (sgTtr), the gene encoding transthyretin, have been used to induce CRISPR-mediated gene knockdown in mice resulting in a reduction of serum levels of TTR.

CAS No.	2766493-12-1
Chemical Name	CL4F8-6
Synonyms	CL4F8 6， CL4F86, INNYA-23062004
SMILES	C(O)(CCCCCCOC(=O)C(CCCCCC)CCCCCC)(CCCCCCOC(=O)C(CCCCCC)CCCCCC)CCCCN(CCC)CCC
Formula	C51H101NO5
M.Wt	808.35
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Hashiba K, et al. Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of mRNA. Small Science. 2023;3(1):2200071.

View original study figures ↓

Literature-reported formulation composition

Component	mol%	Role
CL4F8-6	50	Ionizable lipid
Cholesterol	38.5	Sterol
DSPC	10	Helper phospholipid
DMG-PEG2000	1.5	PEG lipid
Reported total	100	Source values retained

Component molecular weights and calculated amounts

Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.

Total lipid mass (mg)

Component	Normalized mol%	Amount (µmol)	Weight (mg)
CL4F8-6	50.000	74.6653	60.3557
Cholesterol	38.500	57.4923	22.2294
DSPC	10.000	14.9331	11.7994
DMG-PEG2000	1.500	2.2400	5.6156

Calculated total: 100.0000 mg lipid.

Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.

N/P ratio10

Total lipid:cargo weight ratioNot reported. Cas9 mRNA:sgTTR RNA was optimized at 1:2 w/w for the editing experiment.

Buffer & pHRNA phase: 50 mM citrate, pH 3.5. Dilution/final buffer: 20 mM HEPES with 9% sucrose, pH 7.45.

CargoFirefly-luciferase mRNA, Cy5-labeled mRNA, EGFP mRNA, or Cas9 mRNA plus sgRNA

Administration routeIntravenous

DoseReporter: 0.1 mg/kg. Biodistribution and EGFP: 0.5 mg/kg (EGFP also 1.5 mg/kg). Editing: 0.75, 1.5 or 2.5 mg/kg total RNA.

Animal modelFemale BALB/c mice, 6-8 weeks

Formulation processIonizable lipid, cholesterol, DSPC and DMG-mPEG2k were dissolved in ethanol to 8 mM and mixed with mRNA in 50 mM citrate pH 3.5 using a NanoAssemblr at reported stream flow rates of 3 and 9 mL/min. The dispersion was diluted with HEPES/sucrose and ultrafiltered twice with a 100 kDa device.

Literature-reported performance for the cited formulation

Literature-reportedParticle properties88.78 nm; PDI 0.022; EE 99.4%; pKa 6.14Fresh CL4F8-6 LNPSI Table S1

Literature-reportedLiver Fluc expressionHighest among the tested branched-lipid library0.1 mg/kg Fluc mRNA IV; 6 hPrimary article Fig. 5

Literature-reportedSerum TTR reduction77%2.5 mg/kg total RNA IV; Cas9 mRNA:sgTTR = 1:2 w/w · Day 30Primary article Fig. 6

Literature-reportedLiver editing54%2.5 mg/kg total RNA IV · Day 30Primary article Fig. 6

Literature-reportedSpleen editingNot detectedsgTTR and sgGFP control groups; n=3SI Fig. S8

Selected CL4F8-6 study findings

Experiment	Condition	Reported result
Particle characterization	Fresh formulation	88.78 nm; PDI 0.022; EE 99.4%; pKa 6.14
Reporter mRNA	0.1 mg/kg IV; liver at 6 h	Highest expression in the branched-lipid library
CRISPR editing	2.5 mg/kg total RNA IV; day 30	54% liver editing; 77% serum TTR reduction
Storage	4 C; six months	Particle size and EE unchanged versus initial in the reported study

Primary article Figs. 5-6; SI Table S1 and Fig. S5.

Additional reported findings

Hepatocyte expression

EGFP microscopy showed expression mainly in hepatocytes after IV dosing.

0.5 or 1.5 mg/kg EGFP mRNA; 24 h · Primary article and SI imaging

Six-month storage

CL4F8-6 LNP particle size and encapsulation efficiency were reported unchanged after six months at 4 C.

Study formulation · Primary article and SI Fig. S5a-c

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetHashiba K, et al. Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of mRNA. Small Science. 2023;3(1):2200071. DOI: 10.1002/smsc.202200071
CL4F8-6 single-lipid formulation results are kept separate from mixed-lipid experiments and other CL4F library members.

Open-access article

Published study figures

Original publication figures illustrating the cited formulation and biological results. Select an image to view it at full size.

Figure 6: CL4F8-6 LNPs: liver reporter expression and TTR gene-editing outcomes in mice. — Figure 6 — CL4F8-6 LNPs: liver reporter expression and TTR gene-editing outcomes in mice
CL4F8-6 LNPs: liver reporter expression and TTR gene-editing outcomes in mice. The original microscopy panels show hepatic EGFP expression, while the graphs show serum TTR and liver editing measured in separate RNA-cargo experiments. EGFP panels: 0.5 or 1.5 mg/kg, assessed at 24 h. Editing panels: 0.75, 1.5 or 2.5 mg/kg total RNA; Cas9 mRNA/sgRNA 1:2 by weight; serum TTR at days 9 and 30 and liver editing at day 30; n = 3.
Reproduced from Hashiba et al., Small Science 3, 2200071 (2023), Figure 6. © 2022 The Authors. CC BY 4.0. Original article / figure · CC BY 4.0. Complete original figure; no panels or data altered.

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Lipid component weights only. DMG-mPEG2k uses the website-standard editable MW 2507. RNA, buffer, solvent, process loss, N/P and cargo ratios are not included.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	12.3709 mL	2.4742 mL	1.2371 mL
25 mg	30.9272 mL	6.1854 mL	3.0927 mL
50 mg	61.8544 mL	12.3709 mL	6.1854 mL
100 mg	123.7088 mL	24.7418 mL	12.3709 mL
250 mg	309.2720 mL	61.8544 mL	30.9272 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

CL4F8-6

Pack size & price

Description & Application

Recommended Products

DLinDMA

E10i-494

LP-01

SM-86(Lipid 5)

DOTAP

ALC-0315

CKK-E12

OF-02

FTT5

SM-102